Skip to main content
Log in

Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer

  • Published:
Biotherapy

Abstract

The present study was designed to assess the effects of the protein-bound polysaccharide PSK on the immunological status of patients with gastrointestinal cancer. Twenty-nine gastric and 18 colorectal cancer patients were randomly assigned to either the control or PSK group. Patients in the PSK group were given 3.0 g of PSK orally before surgery, either daily or every other day. Patients in the control group received no PSK. The data of peripheral blood lymphocytes (PBL) were compared before and after administration of PSK, and those of the regional node lymphocytes (RNL) were compared between the control and the PSK group. The results indicate that the effects of PSK were significantly influenced by the duration of administration, but not by the frequency of administration. In the patients belonging to the short term PSK group (administration <14 days), the response of the PBL to PSK and Con A become significantly stronger compared to before the administration of PSK, whereas the cytotoxicity against K562 and KATO-3, and the proportion of CD16+ cells increased significantly in those patients belonging to the long term PSK group (≧14 days). In addition, the proportion of CD9 + 11b + suppressor T cells decreased in the RNL of the short term PSK group, whereas the proportion of CD4 + Leu8 - helper T cells in the RNL increased in the long term PSK group.

These results suggest that the oral administration of PSK leads to the suppression of suppressor cells in the RNL. Thus, increased numbers of cytotoxic effector cells appear to be activated in the PBL while helper T cells predominate in the RNL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

ADCC:

antibody dependent cell-mediated cytotoxicity

Con-A:

concanavalin-A

HBSS:

Hanks' balanced salt solution

IL-2:

interleukin-2

NK:

natural killer

PBL:

peripheral blood lymphocytes

PHA:

phytohemagglutinin

PWM:

poke weed mitogen

rIL-2:

recombinant IL-2

RNL:

regional node lymphocytes

References

  1. Akiyama J, Kawamura T, Gotohda E, Yamada Y, Hosokawa M, Kodama T, Kobayashi H. Immunochemotherapy of transplanted KMT-17 tumor in WKA rats by combination of cyclophosphamide and immunostimulatory protein-bound polysaccharide isolated from basidiomycetes. Cancer Res 1977; 37: 3042–5.

    PubMed  Google Scholar 

  2. Ebina T, Kohya H, Yamaguchi T, Ishida N. Antimetastatic effect of biological response modifiers in the "double grafted tumor system". Jpn J Cancer Res (Gann) 1986; 77: 1034–42.

    Google Scholar 

  3. Ebina T, Kohya H. Antitumor effector mechanism at a distant site in the double grafted tumor system of PSK, a protein-bound polysaccharide preparation. Jpn J Cancer Res (Gann) 1988; 79: 957–64.

    Google Scholar 

  4. Ernest PB, Schicchitano R, Underdown BJ, Bienenstock J. Oral immunization and tolerance. In: Heyworth MF, Jones AI, eds. Immunology of the gastrointestinal tract and liver. New York: Raven Press Ltd., 1988: 125–44.

    Google Scholar 

  5. Ehlike MJ, Reino JM, Eppolito C, Mihich E. The effect of PS-K, a protein bound polysaccharide, an immune responses against allogenic antigens. Int J Immunopharmac 1983; 5: 35–42.

    Google Scholar 

  6. Hanna N, Fidler IJ. Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst 1980; 65: 801–9.

    PubMed  Google Scholar 

  7. Hanna N, Burton RC. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastasis in vivo. J Immunol 1981; 127: 1754–8.

    PubMed  Google Scholar 

  8. Hattori T, Niimoto M, Nakano A, Oride M, Takiyama W, Nishimawari K. Postoperative long-term immunochemotherapy with Mitomycin-C, PSK and FT-207 in gastric cancer patients. Jpn J Surg 1979; 9: 110–7.

    PubMed  Google Scholar 

  9. Ikuzawa M, Matsunaga K, Nishiyama S, Nakajima S, Kobayashi Y, Andoh Y, Kobayashi A, Ohhara M, Ohmura Y, Wada T, Yoshikumi C. Fate and distribution of an antitumor protein-bound polysaccharide PSK (Krestin). Int J Immunopharmac, 1988; 10: 415–23.

    Google Scholar 

  10. Kamisato JK, Nowakowski Maja. Morphological and biochemical alterations of macrophages produced by a glucan, PSK. Immunopharmacology 1988; 16: 89–96.

    PubMed  Google Scholar 

  11. Kano T, Kumashiro R, Tamada R, Kodama Y, Inokuchi K. Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach. Jpn J Surg 1981; 11: 291–6.

    PubMed  Google Scholar 

  12. Kikuchi Y, Kizawa I, Oomori K, Iwano I, Kita T, Kato K. Effects of PSK on interleukin-2 production by peripheral lymphocytes of patients with advanced ovarian carcinoma during chemotherapy. Jpn J Cancer Res (Gann) 1988; 79: 125–30.

    Google Scholar 

  13. Kitani H, Tsuru S, Oguchi M, Watanabe M, Zinnaka Y. Effect of PSK on interferon production in tumor-bearing mice. J Clin Lab Immunol 1984; 15: 211–4.

    PubMed  Google Scholar 

  14. Mickey DD. Combined therapeutic effects of an im munomodulator, PSK, and chemotherapy with carboquone on rat bladder carcinoma. Cancer Chemother Pharmacol 1985; 15: 54–8.

    PubMed  Google Scholar 

  15. Mizushima Y, Yuhki N, Hosokawa M, Kobayashi H. Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PS-K and combined therapeutic effects of PS-K and cyclophosphamide on transplanted tumor in rats. Cancer Res 1982; 42: 5176–80.

    PubMed  Google Scholar 

  16. Mori H, Mihara M, Teshima K, Uesugi U, Xu Q, Sakamoto O, Koda A. Effect of immunostimulants and antitumor agents on tumor necrosis factor (TNF) production. Int J Immunopharmac 1987; 9: 881–92.

    Google Scholar 

  17. Nio Y, Tsuhitani T, Imai S, Shiraishi T, Kan N, Ohgaki K, Tobe T. Immunomodulating effects of oral administration of PSK. II. Its effects on mice with cecal tumors. J Jpn Soc Cancer Ther 1988; 23: 1068–76.

    Google Scholar 

  18. Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng CC, Imai S, Tobe T.In vitro immunomodulating effects of protein-bound polysaccharide, PSK on peripheral blood, regional nodes and spleen lymphocytes in patients with gastric cancer. Cancer Immunol Immunother 1991; 32: 335–41.

    PubMed  Google Scholar 

  19. Ohno R, Yamada K, Masaoka T, Ohshima T, Amaki I, Hirota Y, Horikoshi N, Horiuchi A, Imai K, Kimura I, Kitajima K, Nakamura H, Nakamura T, Ohta Y, Sakai Y, Tanaka M, Tsubaki K, Uchino H, Ogawa N, Kimura K. A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother 1984; 18: 149–54.

    PubMed  Google Scholar 

  20. Sabolovic D, Galoppin L. Effect of a protein bound polysaccharide (PS-K) on the tumor development and infections in splenectomized rats and mice. Int J Immunopharmac 1986; 8: 41–6.

    Google Scholar 

  21. Toge T, Yamaguchi Y, Kegoya Y, Baba N, Yanagawa E, Hattori T. Blocking of lymphocyte surface binding sites for the soluble suppressor factor by protein-bound polysaccharide, PSK. Int J Immunopharmac 1989; 11: 9–12.

    Google Scholar 

  22. Torisu M. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990; 31: 261–8.

    PubMed  Google Scholar 

  23. Tsukagoshi S, Ohashi F. Protein-bound polysaccharide preparation, PS-K, effective against mouse sarcoma-180 and rat ascites hepatoma AH-13 by oral use. Gann 1974; 65: 557–8.

    PubMed  Google Scholar 

  24. Tsuru S, Nomoto K. Effect of PSK on specific tumor immunity to syngeneic tumor cells. J Clin Lab Immunol 1983; 4: 215–9.

    Google Scholar 

  25. Usui S, Urano M, Koike S, Kobayahi Y. Brief communication: effects of PS-K, a protein polysaccharide, on pulmonary metastasies of a C3H mouse squamous cell carcinoma. J Natl Cancer Inst 1976; 56: 185–7.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nio, Y., Tsubono, M., Tseng, CC. et al. Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Biotherapy 4, 117–128 (1992). https://doi.org/10.1007/BF02171756

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02171756

Key words

Navigation